Table 3.
Potential anti-psoriasis drugs predicted by medical genetics of targets and related literature/patents.
| Target | Genetic Disease Pathogenesis a | Drug (Mode of Action) b | Current Drug Indication c | Reference |
|---|---|---|---|---|
| EGFR | GOF | Zalutumumab (inhibitor) | Head and neck cancer | [50] |
| EGFR | GOF | Panitumumab (inhibitor) | Colorectal cancer | [51,52] |
| EGFR | GOF | Necitumumab (inhibitor) | Colorectal cancer | [53,54] |
| IL17-A | GOF | Vidofludimus (inhibitor) | Multiple sclerosis | n.a. d |
| IL17-A | GOF | Cetuximab (inhibitor) | Colorectal cancer; cancer | [55,56] |
| IL1-B | GOF | Diacerein (inhibitor) | Rheumatoid Arthritis; Type 2 Diabetes Mellitus | [57] |
| IL1-B | GOF | Glucosamine (inhibitor) | Osteoarthritis | [58] |
| IL6 | GOF | Ibudilast (inhibitor) | Allergic conjunctivitis | n.a. |
| STAT3 | GOF | Atiprimod (inhibitor) | Inflammatory bowel disease | n.a. |
| STAT3 | GOF | RTA 402 (inhibitor) | Solid tumours | n.a. |
| TNF | GOF | Amrinone (inhibitor) | Congestive heart failure | n.a |
| TNF | GOF | Pomalidomide (inhibitor) | Systemic sclerosis | [59] Patent No.: CN201310039583 |
| TNF | GOF | Certolizumab (inhibitor) | Rheumatold arthritis | [60,61,62] |
| TNF | GOF | Lenalidomide (inhibitor) | Anaemia | [63,64] |
| VEGF | GOF | Bevacizumab (inhibitor) | Glaucoma | [65,66] |
| VEGF | GOF | Minocycline (inhibitor) | Bacterial infection | [67,68] |
| VEGF | GOF | Vandetanib (inhibitor) | Solid tumours | [69] |
a,b Derived from OUgene (http://www.csbio.sjtu.edu.cn); c Derived from TTD, DrugBank; d not available.